
邓旭,博士,讲师,硕士生导师
天然药物化学系
电话:0731-82650386
邮箱:dengxu3817@csu.edu.cn
教育经历
2003.09-2007.07 药学 理学学士 中南大学湘雅医学院
2007.09-2012.07 药物化学 理学博士 中国科学院昆明植物研究所
2014.10-2016.10 有机化学 博士后 武汉大学化学与分子科学学院
工作经历
2012.07-2014.09 植物化学与西部资源持续利用国家重点实验室 | 中国科学院昆明植物研究所 助理研究员
2014.10-2016.09 化学与分子科学学院 | 武汉大学 博士后
2016.09-至今 药物化学系 | 中南大学湘雅药学院 讲师
研究领域和研究方向
1,导向活性天然产物骨架高效构建的合成方法学研究;
2,活性天然产物结构修饰与构效关系研究;
3,中药复方的药效物质基础研究;
4,新颖活性天然产物的作用机制与化学生物学研究;
主持科研项目:
1, Akuammiline型吲哚生物碱Corymine和Echitamine的合成研究(项目批准号:21302193),国家自然科学基金青年基金,25万元,2014.01-2016.12, 项目负责人;
2, 过渡金属催化、氧气介导的环化反应及其在天然产物合成中的应用(项目批准号:2015FB167),云南省应用基础研究计划面上项目,10万元,2015.07-2018.06,项目负责人;
3, 新型Cn*-TunePhos及其在烯炔环异构化反应中的应用(项目批准号:2015M572189), 中国博士后科学基金面上项目,5万元,2015.01-2016.12,项目负责人;
4, Akuammiline型吲哚生物碱corymine的合成研究(项目批准号:292014312D11016),中国科学院“西部之光”人才培养计划西部博士项目,10万元,2014.01-2016.12 ,项目负责人;
代表性论文(一作):
(1). Xu Deng, Yu-Qing Guan, Ning-Ning Huo, Ya-Jing Wang, Hui Lv, Xu-Mu Zhang*, An efficient and modular route to C3*-TunePhos type ligands, Synthesis, 2017, 49, 3726-3730 (IF = 2.652).
(2). Xu Deng, Shao-Fei Ni, Zheng-Yu Han, Yu-Qing Guan, Hui Lv, Li Dang*, Xu-Mu Zhang*, Enantioselective rhodium-catalyzed cycloisomerization of (E)-1,6-enynes. Angewandte Chemie International Edition, 2016, 55, 6295-6299. (IF = 11.709).
(3). Bai-Xin Ye#, Xu Deng#, Li-Dong Shao, Ying Lu, Run Xiao, Yi-Jie Liu, Yi Jin, Yin-Yin Xie, Mei Dong, Yan Zhao, Ming Gao, Shun Ma, Liu-Fei Luo, Lian-Ru, Juan He, Yi Chen, Min Deng, Ting-Xi Liu, Qin-Shi Zhao*, Sai-Juan Chen*, Zhu Chen*, Vibsanin B preferentially targets HSP90b, inhibit interstitial leukocyte migration and ameliorates experimental autoimmue encephalomyelitis, Journal of Immunology, 2015, 194, 4489-4497. (#共同第一作者, IF = 4.985).
(4). Xu Deng, Kang-Jiang Liang, Xiao-Gang Tong, Ming Ding, Da-Shan Li, Cheng-Feng Xia*, Biomimetic synthesis of chaetominine epimers via copper-catalyzed radical cyclization, Tetrahedron, 2015, 71, 3699-3704. (IF = 2.645)
(5) Xu Deng, Kang-Jiang Liang, Xiao-Gang Tong, Ming Ding, Da-Shan Li, Cheng-Feng Xia*, Copper-catalyzed radical cyclization to access 3-hydroxypyrroloindoline: biomimetic synthesis of protubonine A, Organic Letters, 2014, 16, 3276-3279. (IF = 6.732)
(6) Ling-Mei Kong#, Xu Deng#, Zhi-Li Zuo, Han-Dong Sun, Qin-Shi Zhao*, Yan Li*, Identification and validation of P50 as the cellular target of Eriocalyxin B, Oncotarget, 2014, 5, 11354-11364 (#共同第一作者, IF = 5.008)
(7) Xu Deng, Yu Shen, Jing Yang, Juan He, Yu Zhao, Li -Yan Peng, Ying Leng*, Qin-Shi Zhao*, Discovery and Structure-Activity Relationships of ent-Kaurene Diterpenoids as Potent and Selective 11β-HSD1 Inhibitors: Potential Impact in Diabetes, European Journal of Medicinal Chemistry, 2013, 65, 403-414. (IF = 4.519)
(8). Jing-Jie Zhang#, Guang-Xun Gao#, Liang Chen#, Xu Deng#, Jing-Xia Li, Yong-Hui Yu, Dong-Yun Zhang, Fei Li, Min Zhang, Qin-Shi Zhao*, Chuan-Shu Huang*, Cheliesisin A inhibits EGF-induced cell transformation with stablization of p53 protein via a hydrogen peroxide/Chk1 dependent axis, Cancer prevention Research, 2013, 6, 949-958; (#共同第一作者, IF = 3.887)
(9). Xu Deng, Ling-Mei Kong, Yu Zhao, Juan, He, Li-Yan Peng, Yan Li*, Qin-shi Zhao*, Exploring of drug leads from diversity-oriented Michael-acceptor library derived from natural products, Natural products and Bioprospecting, 2012, 2, 210-216.
(10). Xu Deng, Jia Su, Yu Zhao, Li-Yan Peng, Yan Li, Zhu-Jun Yao*, Qin-Shi Zhao*, Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles, European Journal of Medicinal Chemistry, 2011, 46, 4238-4244. (IF = 4.519)